https://scholars.lib.ntu.edu.tw/handle/123456789/512617
標題: | Comparable clinical outcomes in patients with HER2-mutant and EGFR-mutant lung adenocarcinomas | 作者: | Gow C.-H. Chang H.-T. Lim C.-K. Liu C.-Y. JIN-SHING CHEN JIN-YUAN SHIH |
公開日期: | 2017 | 出版社: | Blackwell Publishing Inc. | 卷: | 56 | 期: | 5 | 起(迄)頁: | 373-381 | 來源出版物: | Genes Chromosomes and Cancer | 摘要: | HER2 is a major proliferative driver in lung cancer. HER2 gene aberrations impact the prognosis of lung adenocarcinoma (ADC). A one-step reverse transcription-polymerase chain reaction was performed using RNA samples from 888 Asian lung cancer patients to detect HER2, EGFR, KRAS, ALK, and ROS1 mutations. The demographic data and treatment outcomes of HER2 mutation-positive lung ADC patients were analyzed and compared to those with HER2 mutation-negative tumors. HER2 mutation was identified in 40 (4.5%) lung ADC patients. HER2 mutations tended to occur in male patients with advanced-stage disease and never-smokers. A775_G776insYVMA (n = 22, 55%) was the most prevalent HER2 mutation, followed by P780_Y781insGSP (n = 4, 10%). For patients diagnosed with stage-IIIB/IV disease, HER2-mutant patients showed clinical outcomes comparable to EGFR-mutant patients (P = 0.721, log-rank test) and a better overall survival (OS) compared to patients lacking driver mutations in the investigated genes (P = 0.033, Breslow test). Specifically, lung ADC patients with stage-IV HER2-mutant tumors treated with chemotherapy or targeted agents, even without afatinib or anti-HER2 targeted therapy, showed similar clinical outcomes to lung ADC patients harboring EGFR exon 19 deletion or L858R mutations (P = 0.870). In addition, multivariate analysis indicated that HER2 mutation status was not a major risk factor for diminished OS in stage-IV lung cancer. In conclusion, lung ADC harboring HER2 mutations showed distinct characteristics from other driver mutations, including increased chemosensitivity with in advanced stage disease. ? 2017 Wiley Periodicals, Inc. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85013140556&doi=10.1002%2fgcc.22442&partnerID=40&md5=44d997695752cbe260fb4edb0f9ea063 https://scholars.lib.ntu.edu.tw/handle/123456789/512617 |
ISSN: | 1045-2257 | DOI: | 10.1002/gcc.22442 | SDG/關鍵字: | afatinib; ALK protein; docetaxel; epidermal growth factor receptor; epidermal growth factor receptor 2; erlotinib; gefitinib; K ras protein; paclitaxel; pemetrexed; protein; ROS1 protein; trastuzumab; unclassified drug; antineoplastic agent; EGFR protein, human; epidermal growth factor receptor; epidermal growth factor receptor 2; ERBB2 protein, human; tumor marker; adult; aged; Article; Asian; cancer staging; chemosensitivity; clinical outcome; exon; female; gene mutation; human; human tissue; lung adenocarcinoma; major clinical study; male; molecularly targeted therapy; mutation; overall survival; priority journal; retrospective study; risk assessment; treatment outcome; adenocarcinoma; Asian continental ancestry group; comparative study; follow up; genetics; Lung Neoplasms; middle aged; pathology; prognosis; survival rate; very elderly; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian Continental Ancestry Group; Biomarkers, Tumor; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Receptor, Epidermal Growth Factor; Receptor, ErbB-2; Retrospective Studies; Survival Rate |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。